2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 596

Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease
Abstract Number: 2192

Association Between Quality of Sleep and Quality of Life Among Japanese Systemic Lupus Erythematosus Outpatients
Abstract Number: 3133

Association Between Quantitatively Measured Infrapatellar Fat Pad High Signal Intensity Alteration and Knee Structural and Symptomatic Abnormalities in Patients with Symptomatic Knee Osteoarthritis
Abstract Number: 2654

Association Between Rheumatoid Factor Positivity and Effects of Treatment with a First Biologic Agent in Rheumatoid Arthritis
Abstract Number: 3096

Association Between Smoking and Psoriatic Arthritis Among Psoriasis Patients and the General Population: Data from National Inpatient Sample
Abstract Number: 675

Association Between Structural Lesions in the Sacroiliac Joints and Spinal Inflammatory Lesions in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2200

Association of Active Commuting and Physical Activity in Women with Fibromyalgia
Abstract Number: 2180

Association of Anterior Cruciate Ligament/Meniscal Injury with Knee Function, Knee Pain, and Knee Osteoarthritis in Military Officers
Abstract Number: 509

Association of Anti-Citrullinated Protein Antibody Positivity and Titer Levels to Low Hand BMD, and the Consequence of Low Hand BMD on DAS28 (CRP) Remission in Established RA: Findings from a US Observational Cohort
Abstract Number: 2093

Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment
Abstract Number: 1686

Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab
Abstract Number: 3188

Association of Gout with Risk of Advanced Chronic Kidney Disease
Abstract Number: 2714

Association of Polymorphisms of Activation-Induced Cytidine Deaminase with Ankylosing Spondylitis
Abstract Number: 2914

Association of Radiographic Findings in Hand X-Ray with Autoantibodies in Patients with Systemic Sclerosis
Abstract Number: 517

Association of Rheumatoid Arthritis Disease Activity and Clinical Profile with Chronic Periodontitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].